Evoke PLC
21 July 2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION
FOR IMMEDIATE RELEASE
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
21 July 2026
RECOMMENDED ALL-SHARE ACQUISITION
of
evoke plc
by
Bally's Intralot S.A.
to be implemented by means of a scheme of arrangement under Part VIII of the Gibraltar Companies Act 2014
On 5 June 2026, the board of Bally's Intralot S.A. ("Intralot") and the board of evoke plc ("evoke") announced that they had reached an agreement on the terms and conditions of a recommended all-share acquisition by Intralot of the entire issued, and to be issued, ordinary share capital of evoke (the "Acquisition"). The Acquisition is intended to be effected by means of a scheme of arrangement between evoke and evoke Shareholders under Part VIII of the Gibraltar Companies Act 2014.
Publication of the Scheme Document
evoke is pleased to announce that the scheme document containing the full terms and conditions of the Acquisition (the "Scheme Document"), together with the related Forms of Proxy, Forms of Direction, Forms of Instruction, GREEN Form of Election, PINK Form of Election and YELLOW Form of Nomination is being published and sent today to evoke Shareholders and, for information only, to persons with information rights and participants in the evoke Share Plans.
The Scheme Document will be made available on evoke's website at https://www.evokeplc.com/investors/corporate-transactions/proposed-acquisition-by-ballys-intralot. A copy of the Scheme Document has also been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Terms defined in the Scheme Document have the same meanings in this announcement.
Notices of the Court Meeting and General Meeting
As described in the Scheme Document, to become effective the Scheme will require, amongst other things: (i) the approval of a majority in number of Scheme Shareholders present and voting (and entitled to vote), either in person or by proxy at the Court Meeting (or any adjournment thereof), representing not less than 75 per cent. in value of the Scheme Shares voted by such Scheme Shareholders; (ii) the passing of the Special Resolution by the requisite majority of evoke Shareholders at the General Meeting (or any adjournment thereof); and (iii) the subsequent sanction of the Scheme by the Court. The Scheme is also subject to the satisfaction or waiver of the other Conditions and further terms that are set out in the Scheme Document.
Notices of the Court Meeting and the General Meeting, both of which will be held at the offices of Latham & Watkins (London) LLP at One Leadenhall, 1 Leadenhall Street, London EC3V 1AA, United Kingdom on 17 August 2026, are set out in the Scheme Document. The Court Meeting will commence at 10.00 a.m. and the General Meeting at 10.15 a.m. (or, if later, as soon as the Court Meeting has concluded or been adjourned).
It is important that, for the Court Meeting in particular, as many votes as possible are cast, so that the Court may be satisfied that there is a fair and reasonable representation of the opinion of Scheme Shareholders. Scheme Shareholders and evoke Shareholders are therefore strongly encouraged to submit proxy appointments and instructions for the Court Meeting and the General Meeting using any of the methods set out in the Scheme Document as soon as possible and, in any event, by no later than 10.00 a.m. on 13 August 2026 in the case of the Court Meeting and by no later than 10.15 a.m. on 13 August 2026 in the case of the General Meeting (or, in the case of any adjournment, not later than 48 hours (excluding UK non-working days) before the fixed time for the holding of the adjourned meeting).
Holders of evoke Depositary Interests and evoke Nominee Holders are also strongly encouraged to submit voting directions and instructions for the Court Meeting and the General Meeting using any of the methods set out in the Scheme Document as soon as possible and, in any event, by no later than 10.00 a.m. on 12 August 2026 in the case of the Court Meeting and by no later than 10.15 a.m. on 12 August 2026 in the case of the General Meeting (or, in the case of any adjournment, not later than 72 hours (excluding UK non-working days) before the fixed time for the holding of the adjourned meeting).
Recommendation
The evoke Directors, who have been so advised by Morgan Stanley and Rothschild & Co as to the financial terms of the Acquisition, consider the terms of the Acquisition to be fair and reasonable. In providing their advice, Morgan Stanley and Rothschild & Co have taken into account the commercial assessments of the evoke Directors.
Accordingly, the evoke Board unanimously recommends that evoke Shareholders vote (or procure voting) in favour of the Scheme at the Court Meeting and the Special Resolution at the General Meeting, as those evoke Directors who hold or are beneficially entitled to evoke Shares have irrevocably undertaken to do in respect of their (and their connected persons') evoke Shares.
In deciding whether to elect for the Cash Alternative Offer, evoke Shareholders should have regard to their own particular circumstances. In making this decision, the evoke Directors consider that evoke Shareholders should take into account whether they prefer the immediate liquidity of the Cash Alternative Offer as opposed to economic exposure to New Intralot Shares.
evoke Shareholders should read the Scheme Document in its entirety before making a decision with respect to the Scheme.
Timetable
The Scheme Document contains an expected timetable of principal events relating to the Scheme, which is also set out in the Appendix to this announcement. The hearing of the Court to sanction the Scheme is currently expected to be held in the final quarter of 2026 or first quarter of 2027, subject to the prior satisfaction or waiver of the other Conditions set out in the Scheme Document.
If any of the key dates set out in the timetable change, evoke will give notice of this change by issuing an announcement through a Regulatory Information Service and by making such announcement available on evoke's website at https://www.evokeplc.com/investors/corporate-transactions/proposed-acquisition-by-ballys-intralot.
Shareholder helpline
If you have any questions relating to the Scheme Document or the completion and return of the Forms of Proxy, the Forms of Direction, the Forms of Instruction, the GREEN Form of Election, the PINK Form of Election or the YELLOW Form of Nomination, please contact MUFG Corporate Markets on +44 (0) 371 664 0321. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline will be open between 9.00 a.m. - 5.30 p.m., Monday to Friday excluding public holidays in England and Wales. Please note that MUFG Corporate Markets cannot provide advice on the merits of the Acquisition nor give any financial, legal or tax advice and calls may be recorded and monitored for security and training purposes.
Enquiries
|
Deutsche Bank (Joint Financial Adviser to Intralot) |
+44 (0) 207 260 1000 |
|
|
Georgios Georgopoulos |
||
|
Jefferies (Joint Financial Adviser to Intralot) |
+44 (0)20 7029 8000 |
|
|
James Liddy |
||
|
Sodali & Co (PR Adviser to Intralot) |
+44 (0)20 7250 1446 |
|
|
Justin Griffiths |
||
|
evoke |
+44 (0)800 029 3050 |
|
|
Per Widerström, CEO |
||
|
Morgan Stanley & Co. International plc (Joint Financial Adviser to evoke) |
+44 (0)20 7425 8000 |
|
|
Laurence Hopkins |
||
|
Rothschild & Co. (Joint Financial Adviser to evoke) |
+44 (0)20 7280 5000 |
|
|
Edward Duckett Daniel Ross |
||
|
Hudson Sandler (PR Adviser to evoke) |
+44 (0)20 7796 4133 |
|
|
Alex Brennan |
||
Milbank LLP is retained as legal adviser to Intralot.
Latham & Watkins (London) LLP is retained as legal adviser to evoke.
Important notices relating to financial advisers
Jefferies International Limited ("Jefferies"), which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for Intralot and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Intralot for providing the protections afforded to clients of Jefferies nor for providing advice in relation to any matter referred to in this announcement. Neither Jefferies nor any of its affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Jefferies in connection with this announcement, any statement contained herein or otherwise.
Deutsche Bank AG is a stock corporation (Aktiengesellschaft) incorporated under the laws of the Federal Republic of Germany with its principal office in Frankfurt am Main. It is registered with the local district court (Amtsgericht) in Frankfurt am Main under No HRB 30000 and licensed to carry on banking business and to provide financial services. It is subject to supervision by the European Central Bank (ECB), Sonnemannstrasse 22, 60314 Frankfurt am Main, Germany, and the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht or BaFin), Graurheindorfer Strasse 108, 53117 Bonn and Marie-Curie-Strasse 24-28, 60439 Frankfurt am Main, Germany.
Deutsche Bank AG is acting for Intralot and no other person in connection with the matters referred to in this announcement and will not be responsible to any person other than Intralot for providing the protections offered to clients of Deutsche Bank AG nor for providing advice in relation to any matter referred to in this announcement.
Morgan Stanley & Co. International plc ("Morgan Stanley"), which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the PRA and the Financial Conduct Authority ("FCA") in the United Kingdom, is acting exclusively for evoke and for no one else in connection with the Acquisition and neither Morgan Stanley nor any of its affiliates, nor their respective directors, officers, employees or agents will be responsible to anyone other than evoke for providing the protections afforded to its clients or for providing advice in relation to the Acquisition, the contents of this announcement or any other matters referred to in this announcement.
N. M. Rothschild & Sons Limited ("Rothschild & Co"), which is authorised and regulated by the FCA in the United Kingdom, is acting as financial adviser to evoke and no one else in connection with the matters described in this announcement and will not be responsible to anyone other than evoke for providing the protections afforded to clients of Rothschild & Co, or for providing advice in connection with the matters referred to herein. Neither Rothschild & Co nor any of its group undertakings or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Rothschild & Co in connection with this announcement, any statement contained in this announcement or any matter referred to herein. No representation or warranty, express or implied, is made by Rothschild & Co as to the contents of this announcement.
The City Code on Takeovers and Mergers
The City Code on Takeovers and Mergers (the "Code") does not apply to evoke as it is registered in Gibraltar. As a result, a takeover offer for evoke will not be regulated by the UK Panel on Takeovers and Mergers (the "Panel"). evoke's articles of association contain certain provisions requiring evoke to use its reasonable endeavours to apply the rules of the Code to a takeover offer for evoke (except where not in the best interest of evoke to do so), although these do not provide the full protections afforded by the Code and the enforcement of such provisions is not the responsibility of the Panel. Accordingly, evoke Shareholders are reminded that the Panel does not have responsibility, in relation to evoke, for ensuring compliance with the Code and is not able to answer any evoke Shareholders' questions in that regard.
Further information
This announcement is for information purposes only. It does not constitute, and is not intended to constitute, or form part of, any offer, invitation or solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise nor will there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The Acquisition will be made solely pursuant to the terms of the Scheme Document (or, if the Acquisition is implemented by way of an Offer, the Offer Document), which contains the full terms and conditions of the Acquisition, including details of how to vote in respect of the Acquisition. Any vote or decision in respect of, or other response to, the Acquisition should be made only on the basis of the information in the Scheme Document (or, if the Acquisition is implemented by way of an Offer, the Offer Document).
This announcement contains inside information in relation to evoke for the purposes of Article 7 of the Market Abuse Regulation. The person responsible for arranging the release of this announcement on behalf of evoke is Fredrik Ekdahl, General Counsel of evoke.
This announcement does not constitute a prospectus, prospectus equivalent document or exempted document.
If you are in any doubt about the contents of this announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.
Overseas Shareholders
The release, publication or distribution of this announcement in or into certain jurisdictions other than the United Kingdom or Gibraltar may be restricted by law. Persons who are not resident in the United Kingdom or Gibraltar or who are subject to other jurisdictions should inform themselves of, and observe, any applicable requirements. To the fullest extent permitted by applicable law, the companies and persons involved in the Acquisition disclaim any responsibility or liability for the violation of such requirements by any person.
Unless otherwise determined by Intralot, and permitted by applicable law and regulation, the Acquisition shall not be made available, directly or indirectly, in, into or from a Restricted Jurisdiction where to do so would violate the laws in that jurisdiction and no person may vote in favour of the Acquisition by any such use, means, instrumentality or form within a Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation of the laws of that jurisdiction. Accordingly, copies of this announcement and all documents relating to the Acquisition are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in, into or from a Restricted Jurisdiction where to do so would violate the laws in that jurisdiction, and persons receiving this announcement and all documents relating to the Acquisition (including custodians, nominees and trustees) must not mail or otherwise distribute or send them in, into or from such jurisdictions where to do so would violate the laws in that jurisdiction.
The availability of the Acquisition to evoke Shareholders who are not resident in the United Kingdom or Gibraltar may be affected by the laws of the relevant jurisdictions in which they are resident. Persons who are not resident in the United Kingdom or Gibraltar should inform themselves of, and observe, any applicable legal and regulatory requirements.
evoke Shareholders should be aware that the transaction contemplated herein may have tax consequences and that such consequences, if any, are not described herein. evoke Shareholders are urged to consult with appropriate legal, tax and financial advisers in connection with the consequences of the Acquisition on them.
Notice to U.S. evoke Shareholders
The Acquisition relates to shares of a Gibraltar company which are admitted to trading on a UK regulated market, is subject to Gibraltar and UK procedural and disclosure requirements (which are different from those of the US) and is proposed to be implemented under a scheme of arrangement provided for under the company law of Gibraltar. A transaction implemented by means of a scheme of arrangement is not subject to the tender offer rules or the proxy solicitation rules under the US Exchange Act.
Accordingly, the Scheme will be subject to Gibraltar procedural and disclosure requirements and practices, which are different from the procedural and disclosure requirements of United States tender offer and proxy solicitation rules.
The receipt of consideration by a US holder for the transfer of its Shares pursuant to the Scheme may have tax consequences in the United States. Each evoke Shareholder is urged to consult their independent professional adviser immediately regarding the tax consequences of the Acquisition applicable to them, including under applicable United States state, federal and local, as well as overseas and other, tax laws.
Financial information relating to evoke included in this announcement and the Scheme Document has been or shall have been prepared in accordance with accounting standards applicable in the United Kingdom and may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States. If Intralot exercises its right to implement the acquisition of the evoke Shares by way of an Offer, such offer will be made in compliance with applicable US tender offer and securities laws and regulations.
To the extent permitted by applicable law, normal United Kingdom practice and pursuant to Rule 14e-5(b) of the US Exchange Act, Intralot or its nominees, or its brokers (acting as agents), may from time to time make certain purchases of, or arrangements to purchase, shares or other securities of evoke outside of the US, other than pursuant to the Acquisition, until the date on which the Acquisition becomes Effective, lapses or is otherwise withdrawn. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. Any information about such purchases or arrangements to purchase shall be disclosed as required in the UK, shall be reported to a Regulatory Information Service and shall be available on the London Stock Exchange website at www.londonstockexchange.com.
It may be difficult for US evoke Shareholders to enforce their rights and claims arising out of the US federal securities laws, since Intralot and evoke are located in countries other than the United States, and some or all of their officers and directors may be residents of countries other than the United States. US evoke Shareholders may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws. Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to a US court's judgement.
The New Intralot Shares have not been, and will not be, registered under the US Securities Act, or applicable state securities laws. Accordingly, the New Intralot Shares may not be offered, sold, resold, taken up, transferred or delivered, directly or indirectly, in the United States absent registration or an available exemption or a transaction not subject to the registration requirements of the US Securities Act. Accordingly, the New Intralot Shares will not be issued to evoke Shareholders unless Intralot determines that they may be issued pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements of the US Securities Act as provided by Section 3(a)(10) of the US Securities Act or another available exemption.
The New Intralot Shares are expected to be issued in reliance on the exemption from the registration requirements of the US Securities Act set forth in Section 3(a)(10) thereof on the basis of the approval of the Court, and similar exemptions from registration under applicable state securities laws. Section 3(a)(10) of the US Securities Act exempts the issuance of any securities issued in exchange for one or more bona fide outstanding securities from the general requirement of registration under the US Securities Act where the terms and conditions of the issuance and exchange of such securities have been approved by a court of competent jurisdiction that is expressly authorised by law to grant such approval, after a hearing upon the substantive and procedural fairness of the terms and conditions of such issuance and exchange at which all persons to whom it is proposed to issue the securities have the right to appear and receive timely and adequate notice thereof. The Court is authorised to conduct a hearing at which the substantive and procedural fairness of the terms and conditions of the Scheme will be considered. For the purposes of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, evoke will advise the Court before the hearing that the Court's approval of the Scheme will constitute the basis for an exemption from the registration requirements of the US Securities Act, pursuant to Section 3(a)(10).
THE SCHEME AND THE NEW INTRALOT SHARES TO BE ISSUED IN CONNECTION THEREWITH HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER SECURITIES REGULATORY AUTHORITY OF ANY STATE OF THE UNITED STATES, NOR HAS THE SEC OR ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OF THE UNITED STATES PASSED UPON THE FAIRNESS OR THE MERITS OF THIS TRANSACTION OR UPON THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.
Forward-looking statements
This announcement (including information incorporated by reference in this announcement), oral statements made regarding the Acquisition, and other information published by evoke or Intralot (or their respective group companies), contain statements which are, or may be deemed to be, "forward-looking statements". Such forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and on numerous assumptions regarding the business strategies and the environment in which Intralot and evoke shall operate in the future and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements.
The forward-looking statements contained in this announcement relate to Intralot and evoke's future prospects, developments and business strategies, the expected timing and scope of the Acquisition and other statements other than historical facts. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "will look to", "would look to", "plans", "prepares", "anticipates", "expects", "is expected to", "is subject to", "budget", "scheduled", "forecasts", "synergy", "strategy", "goal", "cost-saving", "projects", "intends", "may", "will", "shall" or "should" or their negatives or other variations or comparable terminology. Forward-looking statements may include statements relating to the following: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies and the expansion and growth of Intralot's, evoke's or any member of the evoke Group's or any member of the Intralot Group's operations and potential synergies resulting from the Acquisition; and (iii) the effects of global economic conditions and governmental regulation on Intralot's, evoke's or any member of the evoke Group's or any member of the Intralot Group's business.
Although Intralot and evoke believe that the expectations reflected in such forward-looking statements are reasonable, neither Intralot nor evoke (nor any of their respective associates, directors, officers or advisers) can give any assurance that such expectations will prove to be correct. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements.
These factors include, but are not limited to: (i) the ability to complete the Acquisition; (ii) the ability to obtain requisite regulatory and shareholder approvals and the satisfaction of other Conditions on the proposed terms and schedule; (iii) changes in the global, political, economic, business and competitive environments and in market and regulatory forces; (iv) changes in future exchange and interest rates; (v) changes in tax rates; (vi) future business combinations or disposals; (vii) changes in general economic and business conditions; (viii) changes in the behaviour of other market participants; (ix) changes in the anticipated benefits from the proposed transaction not being realised as a result of changes in general economic and market conditions in the countries in which Intralot and evoke operate; (x) weak, volatile or illiquid capital and/or credit markets; (xi) changes in the degree of competition in the geographic and business areas in which Intralot and evoke operate; (xii) changes in laws or in supervisory expectations or requirements; and (xiii) any epidemic or pandemic or disease outbreak or global health crisis. Other unknown or unpredictable factors could cause actual results to differ materially from those expected, estimated or projected in the forward-looking statements. If any one or more of these risks or uncertainties materialises or if any one or more of the assumptions proves incorrect, actual results may differ materially from those expected, estimated or projected. Such forward-looking statements should therefore be construed in the light of such factors.
Neither evoke nor Intralot, nor any of their respective associates or directors, officers or advisers, provides any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements.
The forward-looking statements speak only at the date of this announcement. All subsequent oral or written forward-looking statements attributable to Intralot, evoke, any member of the Intralot Group or the evoke Group, or any of their respective associates, directors, officers, employees or advisers, are expressly qualified in their entirety by the cautionary statement above.
evoke and Intralot (and their respective associates, directors, officers or advisers) expressly disclaim any intention or obligation to update or revise any forward-looking statements, other than as required by law or by the rules of any competent regulatory authority, whether as a result of new information, future events or otherwise.
Disclosure Requirements
The Code does not apply to evoke as it is registered in Gibraltar. Accordingly, neither evoke Shareholders, Intralot Shareholders nor any other person dealing in evoke Shares or Intralot Shares are required to disclose any of their dealings under the provisions of the Code. However, evoke Shareholders and persons considering the acquisition or disposal of any interest in evoke Shares are reminded that they are subject to the Disclosure Guidance and Transparency Rules made by the FCA under Part VI of FSMA and other applicable regulatory rules regarding transactions in evoke Shares.
Publication on website and availability of hard copies
A copy of this announcement will be made available, subject to certain restrictions relating to persons resident in Restricted Jurisdictions, on Intralot's and evoke's websites at https://www.intralot.com/investor-relations/proposed-acquisition-of-evoke/ and https://www.evokeplc.com/investors/corporate-transactions/proposed-acquisition-by-ballys-intralot, respectively, by no later than 12 noon (London time) on 22 July 2026. For the avoidance of doubt, the contents of these websites or any other website accessible from hyperlinks are not incorporated into and do not form part of this announcement.
You may request a hard copy of this announcement by contacting evoke at ir@evokeplc.com or by telephone on +44 (0)800 029 3050. You may also request that all future documents, announcements and information to be sent to you in relation to the Acquisition should be in hard copy form.
Appendix
Expected timetable of principal events
All times shown are London times unless otherwise stated. All dates and times are based on evoke's and Intralot's current expectations and are subject to change. If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to evoke Shareholders by announcement through a Regulatory Information Service, with such announcement being made available on evoke's website at https://www.evokeplc.com/investors/corporate-transactions/proposed-acquisition-by-ballys-intralot and Intralot's website at https://www.intralot.com/investor-relations/proposed-acquisition-of-evoke/
|
Event |
Time and/or Date |
|
Publication of Scheme Document |
21 July 2026 |
|
Latest time and date for receipt of WHITE Forms of Direction (from evoke DI Holders) and WHITE Forms of Instruction (from evoke Nominee Holders) for the Court Meeting |
10.00 a.m. on 12 August 2026(1) |
|
Latest time and date for receipt of BLUE Forms of Direction (from evoke DI Holders) and BLUE Forms of Instruction (from evoke Nominee Holders) for the General Meeting |
10.15 a.m. on 12 August 2026(2) |
|
Latest time and date for receipt of WHITE Forms of Proxy (for use by Scheme Shareholders) for the Court Meeting |
10.00 a.m. on 13 August 2026(3) |
|
Latest time and date for receipt of BLUE Forms of Proxy (for use by evoke Shareholders) for the General Meeting |
10.15 a.m. on 13 August 2026 (4) |
|
Voting Record Time |
6.00 p.m. on 13 August 2026(5) |
|
Court Meeting |
10.00 a.m. on 17 August 2026 |
|
General Meeting |
10.15 a.m. on 17 August 2026(6) |
|
Last time for evoke Shareholders to qualify as a Material evoke Shareholder |
6.00 p.m. on 27 August 2026(7) |
|
Publication of Intralot General Meeting Invitation |
27 August 2026 |
|
Intralot General Meeting |
18 September 2026 |
|
The following dates and times associated with the Scheme are indicative only and subject to change - see note (8) below |
|
|
Latest time for receipt of GREEN Forms of Election from evoke Shareholders, TTE Instructions for Cash Elections from evoke DI Holders and PINK Forms of Election from evoke Nominee Holders |
1.00 p.m. on D-5 Business Days |
|
Court Hearing |
As soon as reasonably practicable after the satisfaction or waiver of Conditions 3(a)(i), 3(b) and 3(c) as set out in Part A of Part III (Conditions and Further Terms to the Scheme and the Acquisition) of the Scheme Document ("D") |
|
Last day of dealing in, and for registration of transfer of, evoke Depositary Interests |
D+4 Business Days |
|
Last time for lodging YELLOW Form of Nomination in order for New Intralot Shares to be issued to the relevant Designated Account on a date no later than 14 days after the Effective Date |
6.00 p.m. on D+4 Business Days |
|
Disablement of CREST in respect of evoke Depositary Interests |
6.00 p.m. on D+4 Business Days |
|
Scheme Record Time |
6.00 p.m. on D+4 Business Days |
|
Suspension of listing of and dealings in evoke Depositary Interests |
by 8.00 a.m. on D+5 Business Days |
|
Effective Date of the Scheme |
D+5 Business Days |
|
Cancellation of listing and admission to trading of evoke Depositary Interests |
by 8.00 a.m. on D+6 Business Days |
|
Issue of New Intralot Shares |
as soon as practicable following the Scheme becoming Effective and in any event no later than 14 days after the Effective Date |
|
Admission to listing and trading of the New Intralot Shares on Euronext Athens |
by 8.00 a.m. (Central European Time) on the date that falls no later than 14 days after the Effective Date |
|
In respect of: (i) evoke Shareholders who have returned a YELLOW Form of Nomination by the Nomination Return Date, settlement of entitlements to New Intralot Shares to the relevant Designated Account of such evoke Shareholders; and (ii) evoke Non-Nominating Shareholder settlement of entitlements to New Intralot Shares through the Representative (as bare trustee of the evoke Non-Nominating Shareholders) |
as soon as practicable following the Scheme becoming Effective and in any event no later than 14 days after the Effective Date |
|
Latest date for despatch of cheques and settlement through CREST for cash consideration due under the Scheme in respect of Cash Alternative Offer |
14 days after the Effective Date |
|
Last time for lodging YELLOW Form of Nomination in order to receive New Intralot Shares |
6.00 p.m. on the date falling 120 Business Days after the Effective Date(9) |
|
Long Stop Date |
5 September 2027(10) |
Notes:
(1) The WHITE Form of Direction and WHITE Form of Instruction for the Court Meeting must be returned by no later than 10.00 a.m. on 12 August 2026 (or in the case of an adjourned meeting, not less than 72 hours (excluding UK non-working days) prior to the time and date set for the adjourned meeting) to be valid. If an evoke DI Holder or an evoke Nominee Holder wishes to attend, speak and vote directly (i.e. in their own name) at the Court Meeting, they must become a registered holder of one or more of the evoke Shares represented by their evoke Depositary Interests or held directly or indirectly by the MUFG Nominee on their behalf (as applicable) prior to the Voting Record Time by following the instructions set out in paragraph 21 of Part II (Explanatory Statement) of the Scheme Document.
(2) The BLUE Form of Direction and BLUE Form of Instruction for the evoke General Meeting must be returned by no later than 10.15 a.m. on 12 August 2026 (or in the case of an adjourned meeting, not less than 72 hours (excluding UK non-working days) prior to the time and date set for the adjourned meeting) to be valid. If an evoke DI Holder or an evoke Nominee Holder wishes to attend, speak and vote directly (i.e. in their own name) at the General Meeting, they must become a registered holder of one or more of the evoke Shares represented by their evoke Depositary Interests or held directly or indirectly by the MUFG Nominee on their behalf (as applicable) prior to the Voting Record Time by following the instructions set out in paragraph 21 of Part II (Explanatory Statement) of the Scheme Document.
(3) If the WHITE Form of Proxy for the evoke Court Meeting is not returned by the above time, it may be handed to any representative of MUFG Corporate Markets at the venue of the Court Meeting or the Chair of the Court Meeting before the start of the Court Meeting.
(4) The BLUE Form of Proxy for the General Meeting must be returned by no later than 10.15 a.m. on 13 August 2026 (or in the case of an adjourned meeting, not less than 48 hours (excluding UK non-working days) prior to the time and date set for the adjourned meeting) to be valid.
(5) If the Court Meeting or the General Meeting is adjourned, the Voting Record Time for the relevant adjourned meeting will be 6.00 p.m. on the second Business Day before the date set for such adjourned meeting.
(6) To commence at 10.15 a.m. or, if later, immediately after the conclusion or adjournment of the Court Meeting.
(7) A Material evoke Shareholder will be an evoke Shareholder who, as at 6.00 p.m. on 27 August 2026 (being the date falling 10 days after the Court Meeting), holds such number of evoke Shares or evoke Depositary Interests as would entitle such holder, if the Acquisition completed on that date, to receive more than 36,251,310 New Intralot Shares pursuant to the terms of the Acquisition. See paragraph 8 of Part II (Explanatory Statement) of the Scheme Document for an explanation of the rights that Material evoke Shareholders may, subject to the satisfaction of the requirements set out in that paragraph, benefit from following the Effective Date.
(8) These times and dates are indicative only and will depend, among other things, on the date on which (i) the Conditions are satisfied or (if capable of waiver) waived; (ii) the Court sanctions the Scheme; and (iii) the Court Order is delivered to the Registrar of Companies. If any of these times or dates change, evoke will give adequate notice of the changes by issuing an announcement through a Regulatory Information Service (with such announcement being made available on evoke's website at https://www.evokeplc.com/investors/corporate-transactions/proposed-acquisition-by-ballys-intralot and Intralot's website at https://www.intralot.com/investor-relations/proposed-acquisition-of-evoke/). Any further updates or changes to these times and dates will be notified in the same way.
(9) If Holders of evoke Shares and evoke DI Holders have not completed and returned the YELLOW Form of Nomination accompanied by a print-out of their DSS Account particulars by this time and date, they will not receive New Intralot Shares. Instead, Intralot shall instruct the Representative to deliver, as soon as practicable, any New Intralot Shares it holds on trust at the end of the Holding Period to a bank so designated by Intralot, and any such New Intralot Shares will be sold in the market as soon as reasonably practicable after the end of the Holding Period at the best price which can reasonably be obtained at the time of sale and that the net proceeds of sale will be converted into GBP at the Relevant Market Exchange Rate and (after the deduction of Relevant Expenses payable in connection therewith) will be delivered to MUFG Corporate Markets and thereafter settled by means of a cheque for the sum payable to the relevant registered holders of evoke Shares or evoke DI Holder. All such cheques shall be despatched as soon as practicable following the receipt by MUFG Corporate Markets of proceeds of the sale of New Intralot Shares. evoke Shareholders will find a description of the settlement steps in paragraph 18 of Part II (Explanatory Statement) and Part X (Process to Receive New Intralot Shares) of the Scheme Document.
(10) The latest date by which the Scheme must become Effective, which may be extended by agreement between evoke and Intralot with the permission of the Court (if required).
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.